These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 7987989

  • 1. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
    Lauterburg BH, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T.
    Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK, Fahey RC, Dubowy RL, Newton GL, Bernstein ML.
    Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R, Mir O, Camps S, Ropert S, Billemont B, Leconte M, Larousserie F, Anract P, Alexandre J, Goldwasser F.
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M.
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [Abstract] [Full Text] [Related]

  • 12. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH, Elias A, Ryan L.
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine.
    Bernhard MC, Junker E, Hettinger A, Lauterburg BH.
    J Hepatol; 1998 May; 28(5):751-5. PubMed ID: 9625308
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B, Pamir A, Buyukcelik A, Utkan G, Akbulut H, Demirkazik A, Icli F.
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
    Barişta I, Tekuzman G, Yalçin S, Güllü I, Güler N, Ozişik Y, Kars A, Celik I, Türker A, Altundağ K, Zengin N, Uner A, Baltali E, Firat D.
    J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.